Abstract Library

#4620 Impact of the extent of surgical resection on the development of post-operative diabetes in patients undergoing distal pancreatectomy for non-functioning pancreatic neuroendocrine tumours (NF-PanNET)

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are often indolent neoplasms. Surgery is the primary curative approach for localised non-functioning (NF) PanNETs, but it poses a risk of long-term complications, such as diabetes, impacting quality of life.

Conference:

Presenting Author:

Authors: Battistella A, Partelli S, Guccinelli E, Prato F, Andreasi V,

Keywords: Pan NET, distal pancreatectomy, post-operative diabetes, surgical extension,

#4612 Intraoperative beta-probe for pathological tissue detection in GEP-NET patients: A prospective phase II trial

Introduction: Accurate localisation of gastroenteropancreatic neuroendocrine tumours (GEP-NET) is essential for successful radical surgery. Radio guided surgery (RGS) is an innovative technique that may enhance lesion detection.

Conference:

Presenting Author: Bertani E

Authors: Bertani E, Fumagalli Romario U, Collamati F, Ferrari M, Mattana F,

Keywords: radio guided surgery, surgery, neuroendocrine tumour, GEP-NET, gastrointestinal tumour,

#4437 Pancreatic metastases in neuroendocrine neoplasia: A systematic review

Introduction: Neuroendocrine neoplasias (NENs) are a heterogeneous group of neoplasms that often metastasise to distant organs, with the liver and bones as common targets. However, metastases to the pancreas are uncommon, accounting for 2–5% of pancreatic malignancies.

Conference:

Presenting Author:

Authors: Rinzivillo M, Romano E, Dell' Unto E, Marasco M, Panzuto F,

Keywords: pancreatic metastasis, 68Gallium-PET, incidence,

#4389 The LOLA trial: Phase II trial with combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumours (NETs) – Interim results of step 1

Introduction: LOLA is an Italian, multicentre, open-label, double cohort, non-randomised, 3-stage, phase 2 trial aiming to assess the safety and activity of the combination of cabozantinib (CABO) + lanreotide (LAN) in patients (pts) with advanced or metastatic GEP and unknown primary NETs with Ki-67 > 10% or thoracic NET. In NETs sunitinib is the only TKI approved in advanced pancreatic NETs. While CABO has been reported superior to sunitinib in renal cancer its role in NETs is still investigational.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Brizzi M, Giuffrida D, Panzuto F,

Keywords: gastroenteropancreatic neuroendocrine tumour, cabozantinib, lanreotide, clinical trial,

#4322 Clinical outcomes of patients with rectal neuroendocrine tumours smaller than 10mm after endoscopic resection

Introduction: Rectal neuroendocrine tumours (r-NETs) generally have a good prognosis, but up to 20% may be misdiagnosed during endoscopy, risking inadequate treatment. Prognosis factors include tumour size, grading, staging, and lymphovascular invasion, with guidelines recommending endoscopic resection for small, low-grade lesions.

Conference:

Presenting Author:

Authors: Dell' Unto E, Riding G, Rimondi A, Panzuto F, Luong T,

Keywords: Rectal Carcinoid, Rectal Neuroendocrine Tumour, Endoscopic Resection,